RedHill Meets Goals In Phase 1 Study With YELIVA In Advanced Solid Tumors

(RTTNews) - RedHill Biopharma Ltd. (RDHL) said that final results from the Phase I study with YELIVA (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity.

RDHL is currently trading at $10.80, up $0.68 or 6.72 percent.

Twenty-one patients with advanced solid tumors were treated with YELIVA in the study, the majority of which were gastrointestinal cancer patients, including pancreatic, colorectal and cholangiocarcinoma cancers.

A Phase I/II study with YELIVA for refractory or relapsed multiple myeloma is planned to be initiated in the coming weeks and is supported by a $2 million NCI grant awarded to Apogee in conjunction with Duke University; Phase II study to evaluate YELIVA as a radioprotectant to prevent mucositis in cancer patients undergoing therapeutic radiotherapy is planned to be initiated in the second-half of 2016; a Phase II study with YELIVA for the treatment of advanced hepatocellular carcinoma is planned to be initiated in third-quarter of 2016 and is also supported by an NCI grant awarded to MUSC.